Disease reactivation after fingolimod discontinuation in two multiple sclerosis patients

Angelo Ghezzi; Maria A. Rocca; Damiano Baroncini; Pietro Annovazzi; Mauro Zaffaroni; G. Minonzio; Gıancarlo Comı; Massimo Filippi

doi:10.1007/s00415-012-6744-7

Related publications

Article2020

Two-year macular volume assessment in multiple sclerosis patients treated with fingolimod

Alessandro D'Ambrosio, Rocco Capuano, Settimio Rossi, Alvino Bisecco, Michele Lanza, Carlo Gesualdo, Letizia Leocani, Mariaemma Rodegher, Massimo Filippi, Clara Marino, Davide Maimone, Gioacchino Tedeschi, Francesca Simonelli, Antonio Gallo

Article2018

Basal vitamin D levels and disease activity in multiple sclerosis patients treated with fingolimod

Laura Ferrè, Ferdinando Clarelli, Giacomo Sferruzza, Maria A. Rocca, Elisabetta Mascia, Marta Radaelli, Francesca Sangalli, Gloria Dalla Costa, Lucia Moiola, M Aboulwafa, Filippo Martinelli Boneschi, Gıancarlo Comı, Massimo Filippi, Vittorio Martinelli, Federica Esposito

Article2021

Transcriptomic Analysis of Peripheral Monocytes upon Fingolimod Treatment in Relapsing Remitting Multiple Sclerosis Patients

Giacomo Sferruzza, Ferdinando Clarelli, Elisabetta Mascia, Laura Ferrè, Linda Ottoboni, Melissa Sorosina, Silvia Santoro, Lucia Moiola, Vittorio Martinelli, Gıancarlo Comı, Filippo Martinelli Boneschi, Massimo Filippi, Paolo Provero, Federica Esposito

Article2021

Fingolimod as an effective therapeutic strategy for pediatric relapsing-remitting multiple sclerosis: two case reports

Chiara Zanetta, Massimo Filippi, Lucia Moiola

Article2022

Transcriptional Effects of Fingolimod Treatment on Peripheral T Cells in Relapsing Remitting Multiple Sclerosis Patients

Giacomo Sferruzza, Ferdinando Clarelli, Elisabetta Mascia, Laura Ferrè, Linda Ottoboni, Melissa Sorosina, Silvia Santoro, Massimo Filippi, Paolo Provero, Federica Esposito